Online Supplement

Original Research
Randomized Double-Blinded Pilot Study of Doxycycline for HIV-Associated COPD and Emphysema

Robert J. Kaner, MD[1,2] Sarah L. O'Beirne[1,2*] Amy Krambrink[3] Cathie Spino[3] He Sarina Yang[4] Yuan-Shan Zhu[5,6] Ronald G. Crystal[1,2] Marshall J. Glesby[7]

[1]Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, New York, United States

[2]Department of Genetic Medicine, Weill Cornell Medicine, New York, New York, United States

[3]Department of Biostatistics – SABER, University of Michigan, Ann Arbor, Michigan, United States

[4]Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, United States


[5]Clinical and Translational Science Center, Weill Cornell Medicine, New York, New York, United States

[6]Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, New York, United States

[7]Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States


[*]*Current affiliation: University College, Dublin, Ireland*

Supplemental Figure 1.




Boxplots of FEV_1 percent predicted by treatment at weeks 0, 12, and 24. The upper horizontal line of the box represents the 75th percentile; the middle line represents the 50th percentile; the lower line represents the 25th percentile. Whiskers extend from the box to the minimum and maximum values.

Supplemental Figure 2.




Boxplots of FVC percent predicted by treatment at weeks 0, 12, and 24. The upper horizontal line of the box represents the 75th percentile; the middle line represents the 50th percentile; the lower line represents the 25th percentile. Whiskers extend from the box to the minimum and maximum values.

Supplemental Figure 3.




Boxplots of FEV/FVC ratio by treatment at weeks 0, 12, and 24. The upper horizontal line of the box represents the 75th percentile; the middle line represents the 50th percentile; the lower line represents the 25th percentile. Whiskers extend from the box to the minimum and maximum values, excluding outliers. Outliers are denoted by single data points (circles) beyond the whiskers.

Supplemental Figure 4.




BAL neutrophil count (x10^3/ml) at Weeks 0 and 12 by treatment. The upper horizontal line of the box represents the 75th percentile; the middle line represents the 50th percentile; the lower line represents the 25th percentile. Whiskers extend from the box to the minimum and maximum values, excluding outliers. Outliers are denoted by single data points (circles) beyond the whiskers.

Supplemental Figure 5.




BAL eosinophil count (x10^3/ml) at Weeks 0 and 12 by treatment. The upper horizontal line of the box represents the 75th percentile; the middle line represents the 50th percentile; the lower line represents the 25th percentile. Whiskers extend from the box to the minimum and maximum values, excluding outliers. Outliers are denoted by single data points (circles) beyond the whiskers.

Supplemental Figure 6.




BAL lymphocyte count (x10^3/ml) at Weeks 0 and 12 by treatment. The upper horizontal line of the box represents the 75th percentile; the middle line represents the 50th percentile; the lower line represents the 25th percentile. Whiskers extend from the box to the minimum and maximum values, excluding outliers. Outliers are denoted by single data points (circles) beyond the whiskers.

Supplemental Figure 7.



Change in BAL lymphocytes (absolute lymphocyte count at week 12 minus absolute lymphocyte count at week 0) vs Week 12 BAL doxycycline concentration. A regression line showing the linear relationship between the change in lymphocyte count and week 12 BAL doxycycline level is shown in red.


Supplemental Figure 8.



Change in Eosinophils (absolute eosinophil count at week 12 minus absolute eosinophil count at week 0) *vs* Week 12 BAL doxycycline concentration. A regression line showing the linear


relationship between the change in eosinophil count and week 12 BAL doxycycline level is shown in red.

Supplemental Figure 9.




Serum C-Reactive Protein (CRP) vs Serum Doxycycline Concentration at Week 24. A regression line showing the linear relationship between CRP and doxycycline concentration is shown in red.

Supplemental Figure 10.




Serum Interferon-γ (IFN-γ) vs Serum Doxycycline Concentration at Week 24. A regression line showing the linear relationship between IFN-γ and doxycycline concentration is shown in red.

Supplemental Figure 11.




Serum Interleukin-6 (IL-6) vs Serum Doxycycline Concentration at Week 24. A regression line showing the linear relationship between IL-6 and doxycycline concentration is shown in red.

Supplemental Figure 12.



Serum Tumor Necrosis Factor-α (TNF-α) vs Serum Doxycycline Concentration at Week 24. A regression line showing the linear relationship between TNF-α and doxycycline concentration is shown in red.

Supplemental Figure 13.



Serum Soluble CD14 (sCD14) vs Serum Doxycycline Concentration at Week 12. A regression line showing the linear relationship between sCD14and doxycycline concentration is shown in red.